Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 80

1.

Obstetric risks and outcomes of refugee women at a single centre in Toronto.

Kandasamy T, Cherniak R, Shah R, Yudin MH, Spitzer R.

J Obstet Gynaecol Can. 2014 Apr;36(4):296-302. doi: 10.1016/S1701-2163(15)30604-6.

PMID:
24798666
2.

Two year prognosis of sarcoidosis: the ACCESS experience.

Judson MA, Baughman RP, Thompson BW, Teirstein AS, Terrin ML, Rossman MD, Yeager H Jr, McLennan G, Bresnitz EA, DePalo L, Hunninghake G, Iannuzzi MC, Johns CJ, Moller DR, Newman LS, Rabin DL, Rose C, Rybicki BA, Weinberger SE, Knatterud GL, Cherniak R; ACCESS Research Group.

Sarcoidosis Vasc Diffuse Lung Dis. 2003 Oct;20(3):204-11.

PMID:
14620163
3.

Mannoprotein from Cryptococcus neoformans promotes T-helper type 1 anticandidal responses in mice.

Pietrella D, Mazzolla R, Lupo P, Pitzurra L, Gomez MJ, Cherniak R, Vecchiarelli A.

Infect Immun. 2002 Dec;70(12):6621-7.

4.

Clinical characteristics of patients in a case control study of sarcoidosis.

Baughman RP, Teirstein AS, Judson MA, Rossman MD, Yeager H Jr, Bresnitz EA, DePalo L, Hunninghake G, Iannuzzi MC, Johns CJ, McLennan G, Moller DR, Newman LS, Rabin DL, Rose C, Rybicki B, Weinberger SE, Terrin ML, Knatterud GL, Cherniak R; Case Control Etiologic Study of Sarcoidosis (ACCESS) research group.

Am J Respir Crit Care Med. 2001 Nov 15;164(10 Pt 1):1885-9.

PMID:
11734441
5.

Potent inhibition of neutrophil migration by cryptococcal mannoprotein-4-induced desensitization.

Coenjaerts FE, Walenkamp AM, Mwinzi PN, Scharringa J, Dekker HA, van Strijp JA, Cherniak R, Hoepelman AI.

J Immunol. 2001 Oct 1;167(7):3988-95.

6.

Role of mannoprotein in induction and regulation of immunity to Cryptococcus neoformans.

Pietrella D, Cherniak R, Strappini C, Perito S, Mosci P, Bistoni F, Vecchiarelli A.

Infect Immun. 2001 May;69(5):2808-14.

7.

Cryptococcal glucuronoxylomannan delays translocation of leukocytes across the blood-brain barrier in an animal model of acute bacterial meningitis.

Lipovsky MM, Tsenova L, Coenjaerts FE, Kaplan G, Cherniak R, Hoepelman AI.

J Neuroimmunol. 2000 Nov 1;111(1-2):10-4.

PMID:
11063816
8.

Pathogenesis of Cryptococcus neoformans is associated with quantitative differences in multiple virulence factors.

Blackstock R, Buchanan KL, Cherniak R, Mitchell TG, Wong B, Bartiss A, Jackson L, Murphy JW.

Mycopathologia. 1999;147(1):1-11.

PMID:
10872510
9.

Early induction of interleukin-12 by human monocytes exposed to Cryptococcus neoformans mannoproteins.

Pitzurra L, Cherniak R, Giammarioli M, Perito S, Bistoni F, Vecchiarelli A.

Infect Immun. 2000 Feb;68(2):558-63.

10.

Cryptococcus neoformans and its cell wall components induce similar cytokine profiles in human peripheral blood mononuclear cells despite differences in structure.

Walenkamp AM, Chaka WS, Verheul AF, Vaishnav VV, Cherniak R, Coenjaerts FE, Hoepelman IM.

FEMS Immunol Med Microbiol. 1999 Dec;26(3-4):309-18.

11.

Phenotypic switching in Cryptococcus neoformans results in changes in cellular morphology and glucuronoxylomannan structure.

Fries BC, Goldman DL, Cherniak R, Ju R, Casadevall A.

Infect Immun. 1999 Nov;67(11):6076-83.

12.

In vitro and in vivo stability of a Cryptococcus neoformans [corrected] glucuronoxylomannan epitope that elicits protective antibodies.

Cleare W, Cherniak R, Casadevall A.

Infect Immun. 1999 Jun;67(6):3096-107. Erratum in: Infect Immun 1999 Jul;67(7):3702.

13.

Structural characterization of the galactoxylomannan of Cryptococcus neoformans Cap67.

Vaishnav VV, Bacon BE, O'Neill M, Cherniak R.

Carbohydr Res. 1998 Jan;306(1-2):315-30.

PMID:
9691456
15.
17.
18.

Microevolution of a standard strain of Cryptococcus neoformans resulting in differences in virulence and other phenotypes.

Franzot SP, Mukherjee J, Cherniak R, Chen LC, Hamdan JS, Casadevall A.

Infect Immun. 1998 Jan;66(1):89-97.

19.
20.

Induction of TNF-alpha in human peripheral blood mononuclear cells by the mannoprotein of Cryptococcus neoformans involves human mannose binding protein.

Chaka W, Verheul AF, Vaishnav VV, Cherniak R, Scharringa J, Verhoef J, Snippe H, Hoepelman AI.

J Immunol. 1997 Sep 15;159(6):2979-85.

PMID:
9300722
22.

Structure and biological activities of acapsular Cryptococcus neoformans 602 complemented with the CAP64 gene.

Chang YC, Cherniak R, Kozel TR, Granger DL, Morris LC, Weinhold LC, Kwon-Chung KJ.

Infect Immun. 1997 May;65(5):1584-92.

23.

Structure of the capsular polysaccharide of Clostridium perfringens Hobbs 5 as determined by NMR spectroscopy.

Kalelkar S, Glushka J, van Halbeek H, Morris LC, Cherniak R.

Carbohydr Res. 1997 Apr 21;299(3):119-28.

PMID:
9163894
24.

Mannoproteins of Cryptococcus neoformans induce proliferative response in human peripheral blood mononuclear cells (PBMC) and enhance HIV-1 replication.

Orendi JM, Verheul AF, De Vos NM, Visser MR, Snippe H, Cherniak R, Vaishnav VV, Rijkers GT, Verhoef J.

Clin Exp Immunol. 1997 Feb;107(2):293-9.

26.
27.

Structure of the O-deacetylated glucuronoxylomannan from Cryptococcus neoformans Cap70 as determined by 2D NMR spectroscopy.

Bacon BE, Cherniak R, Kwon-Chung KJ, Jacobson ES.

Carbohydr Res. 1996 Mar 22;283:95-110.

PMID:
8901265
28.

Serotyping of Cryptococcus neoformans by dot enzyme assay.

Belay T, Cherniak R, O'Neill EB, Kozel TR.

J Clin Microbiol. 1996 Feb;34(2):466-70.

29.
30.

Variation in the structure of glucuronoxylomannan in isolates from patients with recurrent cryptococcal meningitis.

Cherniak R, Morris LC, Belay T, Spitzer ED, Casadevall A.

Infect Immun. 1995 May;63(5):1899-905.

32.

Polysaccharide antigens of the capsule of Cryptococcus neoformans.

Cherniak R, Sundstrom JB.

Infect Immun. 1994 May;62(5):1507-12. Review.

33.

Glucuronoxylomannan of Cryptococcus neoformans obtained from patients with AIDS.

Cherniak R, Morris LC, Meyer SA, Mitchell TB.

Carbohydr Res. 1993 Nov 3;249(2):405-13. No abstract available.

PMID:
8275508
34.
36.
37.
38.
39.

Galactoxylomannans of Cryptococcus neoformans.

James PG, Cherniak R.

Infect Immun. 1992 Mar;60(3):1084-8.

41.

Complete assignment of the 1H- and 13C-n.m.r. spectra of the O-deacetylated glucuronoxylomannan from Cryptococcus neoformans serotype B.

Skelton MA, van Halbeek H, Cherniak R.

Carbohydr Res. 1991 Dec 16;221:259-68. No abstract available.

PMID:
1816923
42.

Glucuronoxylomannan of Cryptococcus neoformans serotype B: structural analysis by gas-liquid chromatography-mass spectrometry and 13C-nuclear magnetic resonance spectroscopy.

Turner SH, Cherniak R.

Carbohydr Res. 1991 Apr 2;211(1):103-16. Erratum in: Carbohydr Res 1992 Apr 27;228(2):c1.

PMID:
1773425
43.

Facilitated isolation, purification, and analysis of glucuronoxylomannan of Cryptococcus neoformans.

Cherniak R, Morris LC, Anderson BC, Meyer SA.

Infect Immun. 1991 Jan;59(1):59-64.

44.

Polysaccharides from Peptostreptococcus anaerobius and structure of the species-specific antigen.

Stortz CA, Cherniak R, Jones RG, Treber TD, Reinhardt DJ.

Carbohydr Res. 1990 Oct 15;207(1):101-20.

PMID:
2076510
45.

4-Methylmorpholine N-oxide-methyl sulfoxide soluble glucan of Piptoporus betulinus.

James PG, Cherniak R.

Carbohydr Res. 1990 Sep 30;206(1):167-72. No abstract available.

PMID:
2081343
46.

Cell-wall glucans of Cryptococcus neoformans Cap 67.

James PG, Cherniak R, Jones RG, Stortz CA, Reiss E.

Carbohydr Res. 1990 Apr 2;198(1):23-38.

PMID:
2191777
47.

An anti-Cryptococcus neoformans monoclonal antibody directed against galactoxylomannan.

van de Moer A, Salhi SL, Cherniak R, Pau B, Garrigues ML, Bastide JM.

Res Immunol. 1990 Jan;141(1):33-42.

PMID:
2189167
48.
49.

Localization of mannoprotein in Cryptococcus neoformans.

Vartivarian SE, Reyes GH, Jacobson ES, James PG, Cherniak R, Mumaw VR, Tingler MJ.

J Bacteriol. 1989 Dec;171(12):6850-2.

50.

Characterization of Cryptococcus neoformans capsular glucuronoxylomannan polysaccharide with monoclonal antibodies.

Todaro-Luck F, Reiss E, Cherniak R, Kaufman L.

Infect Immun. 1989 Dec;57(12):3882-7.

Supplemental Content

Loading ...
Support Center